A novel Ti35Zr35Nb15Mo5Fe5Cr5 complex concentrated alloy (CCA) with potential for biomedical application was developed by vacuum arc melting and its microstructural evolution, mechanical properties, corrosion and wear behavior, and cytocompatibility were systematically evaluated. The alloy has an experimentally measured density of 6.37 g/cm³, suitable to fulfill the requirement of light weight. XRD analysis revealed that the as-cast and annealed specimens contain two BCC solid solution phases and a TiCr2 type Laves phase. The average microhardness (H) and elastic modulus (E) of the as-cast CCA are 618.39 ± 9.26 HV and 97.32 ± 3.58 GPa, respectively. Moreover, the yield strength (YS) of the as-cast alloy, estimated from elastoplastic analysis of the microindentation data, is 1203.94 ± 30.28 MPa. However, the CCA annealed at 1100˚C exhibits a microhardness of 833.08 ± 7.58 HV and a YS of 1669.65 ± 24.79 MPa, with the elastoplastic stress-strain response revealing no significant loss of plasticity due to the increased hard Laves phase. Corrosion and wear tests conducted in simulated body fluid confirmed the alloy's excellent corrosion and wear resistance. Cell culture experiments with MG-63 and HEK-293 cells demonstrated superior cell viability and proliferation compared to CP-Ti and 316 L SS. Moreover, confocal fluorescence images of MG-63 cells stained with AO/EtBr, Rh-123, and DCFH-DA revealed that the present CCA exhibits good biocompatibility. Thus, a comprehensive combination of low density, compatible elastic modulus, good strength with adequate plasticity, and sufficient corrosion resistance and biocompatibility were successfully achieved, unraveling significant potential of the alloy for biomedical applications.
Read full abstract